Rational Growth in a Trillion-Yuan Track: Key Pathways and Future Landscape of Synthetic Biology Industrialization

Amid a tightening financing environment and a reevaluation of commercialization cycles,Synthetic biology is transitioning from the stage of “validating technical feasibility” to a critical inflection point focused on pathways for real-world implementation.Which application scenarios can first establish a stable business model? How can technological capabilities undergo real-world validation amidst engineering scale-up and cost constraints? These core questions are becoming new imperatives for industry development.

As an interdisciplinary field that reconstructs life systems through engineering thinking,Synthetic Biology Has Continuously Advanced Application Exploration Across Multiple Industries in Recent Years. In the pharmaceutical manufacturing sector, it is used to enhance the production efficiency of key raw materials and intermediates; in the food and nutritional health sector, related technologies are attempting to replace traditional production pathways with more sustainable alternatives; in fields such as materials and agriculture, bio-based manufacturing applications are also emerging.At the policy level, documents such as the “14th Five-Year Plan for Bioeconomy Development” explicitly propose supporting the development and industrialization of technologies related to biomanufacturing., but how to truly bridge the gap between laboratory achievements and large-scale application remains a practical challenge facing the industry as a whole.

Against this backdrop, the 13th episode of the “China Innovative Medical Assets Living Room” Transaction Roundtable, co-hosted by VCBeat and Wei Jieyao, was held online as scheduled on January 22. The roundtable discussion was moderated by Zhou Lixin, Healthcare Partner at Kairui Capital, with participation from Xiong Xiaochao, General Manager of MicroPort Genetech, and Yang Junsheng, Executive Director at Fuyuan Investment.

Centered on the theme “From Technical Experimentation to Commercial Implementation,” the guestsDrawing on corporate practices and investment insights, this discussion delves into the technological evolution of synthetic biology, its commercialization pace, and the construction of its industrial ecosystem., offering a multidimensional perspective on the true state of development in this sector during the new cycle.

As an interdisciplinary field integrating biology, chemical engineering, data science, and engineering, the development of synthetic biology is not driven by a single technology, but ratherPolicy, Technology, CapitalThe result of the combined effects of multiple factors.

Drawing on his more than two decades of in-depth industry experience, Xiong Xiaochao stated: “The pace of development in synthetic biology has never been determined solely by technological maturity; rather, it is the result of the combined effects of regulatory pathway complexity, market substitution logic, and unit product value.“Leveraging the technological accumulation of its parent company, MicroPort Biologics has established a closed-loop system spanning development, iteration, and fermentation scale-up, forming two major business segments: one comprises continuously commercialized active pharmaceutical ingredient (API) products, such as rapamycin-series immunosuppressants, which must follow the stringent regulatory registration pathways for APIs under the GFDA or GMP; the other consists of newly developed synthetic biology products, primarily focused on general health and wellness, including food additives and skin-whitening agents, which utilize market access mechanisms such as GRAS or NDI. These two product categories differ significantly in terms of regulatory requirements, target audiences, and market size.”

Yang Junsheng added from a capital perspective: “Compared with the traditional chemical industry, biomanufacturing technology represents an iterative application direction, achieving significant breakthroughs in dimensions such as new product launch efficiency, production costs, product purity, and process environmental friendliness.” He emphasized that biomanufacturing has been listed by the state as a key area for advancement related to “chokehold” technologies.Policy dividends and market demand are jointly driving the sustained rise in sector热度.In 2023, Fuyuan Investment and Bloomage Biotechnology jointly established an industrial fund with a scale of RMB 1 billion, marking the industry’s first fund themed around synthetic biology and biomanufacturing. The fund focuses on sectors such as consumer health, functional ingredients, and animal healthcare, aiming to remove bottlenecks in the transition from technology development to commercialization.

Zhou Lixin shared K2VC’s investment strategy: “We began focusing on the synthetic biology sector in 2021, investing in upstream service providers such as Sangon Biotech and Tsingke Biological Technology, and leading downstream investments in projects like Zhongyuan Yuze. Our investment practice shows that listed companies with synthetic biology operations or concepts mostly exhibit a ‘double 10-billion’ characteristic, meaning both their sales revenue and market capitalization exceed RMB 10 billion. This is underpinned by strong industrialization capabilities, indicating that beyond technological prowess, industrialization capability is also a core competitive advantage for enterprises.”

In summary, explicit policy support has laid a solid foundation for the development of the synthetic biology sector. Cross-disciplinary integration and the establishment of closed-loop systems on the technological front have unlocked key pathways to industrialization, while precise capital allocation and resource empowerment have accelerated the pace of technology commercialization. The synergistic force generated by these three pillars is driving the synthetic biology sector from fragmented exploration toward a stage of systematic development.

Synthetic biology enters the deep waters of industrialization, with industry focus shifting from isolated technological leadership to stable technology replication, continuous scale-up, and product delivery capabilities.

Xiong Xiaochao pointed out from the perspective of industrial practice that the true technical barriers for synthetic biology enterprises do not lie in how well a single step is performed, but rather in whether an integrated capability has been established spanning strain design, experimental validation, and scaled-up production.Closed-Loop System“Without the ability to replicate laboratory results at the industrial level, there is no basis for claiming technological advantages.” In MicroPort’s practice, this logic has been translated into long-term investments in platform selection, data accumulation, and engineering capabilities.

From a capital perspective, Yang Junsheng pointed out that when evaluating synthetic biology projects, investment institutions have significantly reduced the weight given to single technical indicators, instead focusing more on whether companies possess stable and scalable engineering systems, as well as the resulting cost control and product consistency.

Building on this, the discussion further extended to the topic of “AI + Synthetic Biology,” which has garnered significant attention across the industry. Yang Junsheng believes thatThe core value of artificial intelligence in this field lies more in enhancing efficiency and optimizing costs, rather than in the conceptual layering of technologies.. In practical assessments, capital places greater emphasis on whether AI is truly embedded into key processes such as manufacturing, quality assurance/quality control (QA/QC), and product registration, as well as whether these applications demonstrate improvements in operational metrics like gross margin and expense ratios.

During her moderation, Zhou Lixin further pointed out that, from an investment perspective, “AI + synthetic biology” is gradually transitioning from proof-of-concept to concrete applications. However, its impact typically unfolds incrementally along existing industrial processes, rather than constituting a disruptive restructuring of R&D paradigms. At the current stage, the practical value of AI lies in reducing trial-and-error costs and enhancing decision-making efficiency through algorithmic and data-driven tools, which necessitates clear industrial objectives and long-term data accumulation.

At the corporate level, Xiong Xiaochao also offered a more restrained assessment of the application boundaries of new AI technologies. He stated that enterprises are not pursuing “ultimate advancement” in isolated areas, but are instead more concerned with whether new tools truly serve to amplify R&D efficiency and delivery capabilities.

In brief,Industry perception of technological leadership has evolved: the true gap lies in systems engineering capabilities that transform complex technologies into replicable industrial capacities.

Once the technological pathway is clearly defined, the core challenge for synthetic biology companies is to translate their technical capabilities into market-accepted products.

Xiong Xiaochao stated that the market will not continuously pay for technological advancement alone; what customers truly focus on are product stability at scale, cost controllability, and delivery certainty. To achieve commercial implementation, synthetic biology companies must simultaneously build engineering and delivery capabilities alongside their technical systems; otherwise, their technological advantages are likely to remain confined to the laboratory stage.

Yang Junsheng places greater emphasis on the early integration of commercial thinking. He argues that companies should not complete product R&D before seeking market opportunities; instead, they should engage with potential customers during the small-scale and pilot trial stages to clarify whether the core need addressed by the product is cost substitution, performance enhancement, or supply chain stability. Meanwhile, he points out that enterprises need to build a diversified product portfolio to mitigate risks and avoid reliance on a single product with a short lifecycle.

Zhou Lixin cautioned from the perspectives of pacing and governance that synthetic biology does not imply unlimited expansion. In the early stages of commercialization, companies need to exercise restraint in selecting individual products and market segments, establish clear project approval criteria and capital allocation plans, and reserve capacity for critical phases such as pilot-scale amplification. He pointed out that many enterprises are not lacking in technical capabilities; rather, they are constrained by engineering and organizational capacities during the transition from laboratory research to large-scale production, ultimately failing to establish a stable commercial closed loop.

At the level of industrial implementation, the perspectives of the three panelists also corroborated one another. Xiong Xiaochao pointed out that many enterprises do not lack technical capabilities; rather, they are stuck at the critical juncture between laboratory research and scaled-up production, failing to establish engineering systems commensurate with such scale. Yang Junsheng added that, from an investment evaluation perspective, trends in unit cost reduction, capacity replicability, and stability of customer collaborations often better reflect a company’s potential to cross the scalability threshold than short-term revenue scale does. Zhou Lixin further emphasized that the requirements for technology, capital, and organizational capabilities vary significantly across different stages; if companies cannot transition smoothly between these stages, it will be difficult to truly form a closed commercial loop.

The commercialization of synthetic biology is not a binary choice between “whether the technology is sufficiently advanced” and “whether the market is large enough,” but rather a continuous search for a verifiable and replicable balance between the two.

In the development of the synthetic biology sector, capital has long transcended its role as a mere provider of funds, becoming a “metronome” and “amplifier” on the path to corporate growth.

Xiong Xiaochao stated that the value of capital to enterprises is reflected in two aspects:In the early stages of a company, the room for trial and error provided by capital is more important than the funds themselves., providing enterprises with a comfortable window for technological development to rapidly accumulate experience and advance commercialization; upon entering the commercialization phase, it facilitates connections with leading industry resources, which not only generates orders but also enhances corporate industry recognition and accelerates the commercialization process. Meanwhile, as the industry enters the scale-up and industrialization stage, enterprises’ capital needs have shifted from mere financing to comprehensive expectations for industrial resources, downstream channels, and long-term collaborative capabilities, particularly during the pilot scale-up and production line construction phases.

Yang Junsheng articulated Furong Investment’s empowerment logic: “We aim to serve as the ‘co-pilot,’ not the ‘pilot.’” He stated,Investment institutions should leverage their advantages to provide multi-dimensional support to enterprises.First, it provides assessments of capital market trends and analyses of financing difficulties to help enterprises align with the rhythm of the capital markets. Second, it shares industry insights and competitive landscape information to support corporate decision-making, such as advising companies to avoid entering oversaturated sectors. Third, it facilitates connections with industrial resources, including technology partners and talent pools. Fourth, it leverages brand endorsement to assist enterprises in securing subsequent rounds of financing.

Zhou Lixin added, “Capital can provide companies with advice on capital operations, such as helping later-stage enterprises seize IPO windows and assisting early-stage enterprises in refining their financing plans and financial services.”, but genuine industrial breakthroughs still depend on the inherent strength of enterprises.“KaiLian Capital, as a comprehensive fund, can provide large-scale investments to later-stage companies and make significant bets on early-stage enterprises, facilitating their growth through the integration of upstream and downstream resources. He emphasized, ‘The best investment is one that allows companies to grow organically.’”While providing support, it is also essential to respect the enterprise's development pace and strategic decisions.

As the synthetic biology industry matures, the relationship between capital and the industry is shifting from unidirectional support to bidirectional synergy.Capital is no longer merely a provider of funds; rather, it contributes through strategic timing, resource integration, and long-term partnership., and jointly address the practical challenges encountered during the scale-up and commercialization phases with enterprises.

Synthetic biology still holds significant technological potential, but the industry is shifting from a technology-driven narrative to practical implementation. The focus of enterprises and capital has moved from “whether it can be made” to “whether it can be scaled up for replication and gain sustained market acceptance.” Against this backdrop, changes in the sector’s structure have become a consensus judgment among multiple panelists.

Yang Junsheng judged,Over the next 3–5 years, synthetic biology will bid farewell to its early phase of lax development and enter a period of industry consolidation., with market concentration expected to continue rising. Consolidation is likely to proceed along two main paths: first, horizontal integration, where companies employing different technological approaches merge or acquire one another to expand their market share within the same customer base or application scenarios; second, vertical integration, where downstream application players extend their operations upstream into raw material production and manufacturing to strengthen supply chain stability. In the short term, large-scale consolidation remains constrained by practical conditions. Against a backdrop of sustained policy support and a relatively favorable financing environment, companies are more inclined to prioritize expanding their own business boundaries. He specifically cautioned that entrepreneurs should “plan carefully before acting” and avoid blindly following trends. Only teams with solid technological expertise and clear business plans will be able to navigate industry changes with greater stability and achieve long-term success.

Regarding the issue of corporate positioning during the integration phase, Xiong Xiaochao offered more specific recommendations. He believes that,Synthetic biology companies should not blindly pursue a “large and comprehensive” model, but should clearly define their role within the industry chain.: Either become an irreplaceable key technological node, establish clear advantages in niche application scenarios, or integrate into existing industrial systems such as food, pharmaceuticals, and materials through collaborative approaches. Before entering the market, companies must clarify their target customers, maintain control over scale-up and quality systems, and transform trial-and-error experiences into technical assets.

Zhou Lixin summarized that synthetic biology is poised to become a potential sector where China can lead globally, and entrepreneurs need to focus on niche areas to build core competitiveness. Capital and enterprises should work in tandem: capital needs to leverage its advantages in resource integration and cycle judgment, while enterprises must strengthen their technological and industrialization capabilities. By seizing integration opportunities through industry-investment synergy, both the sector and the enterprises themselves can achieve dual upgrades.

Overall, the synthetic biology sector is bidding farewell to its early stage, which was primarily focused on technical validation, and entering a competitive cycle centered on engineering capabilities and commercialization efficiency. Technology is no longer the sole barrier; the ability to achieve stable scale-up and market delivery within clearly defined application scenarios is becoming the key differentiator among companies. Against this backdrop, as collaboration between the industrial and capital sectors continues to deepen, the path for synthetic biology to transition from the laboratory to large-scale industrial application is becoming increasingly clear.